SLC5A2 and peripheral arterial disease: Regarding medical therapy, patients with unknown CAD status may benefit from SGLT2 inhibitors and low-dose rivaroxaban as PAD was an inclusion criterion per se in the trials, regardless of CAD diagnosis.